CymaBay Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
The following report cites that the company conducts tests on animals to assess a product’s safety profile.
“MBX-2982 also increases incretin hormone levels in animals, which may contribute to its glucose lowering effects.” (Page 20) Read the full document.
CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate. MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. [Source: MarketWatch]
Company Website: http://www.cymabay.com